UFP Technologies Announces Strong Q3 Results
UFP TECHNOLOGIES INC (UFPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. UFP Technologies Announces Strong Q3 Results Newburyport, Mass., November 3, 2026. UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly
How this was made
The 30-second read
Why it matters
The earnings beat provides a fresh catalyst for short‑term price movement, with upside potential if guidance remains optimistic.
Market read
First‑time earnings disclosure for a mid‑cap MedTech supplier, offering a clear trading signal.
What to watch
Higher SG&A expenses and slower margin improvement in legacy operations could temper enthusiasm.
UFP Technologies Announces Strong Q3 Results
Third-quarter sales increased 11.6%, gross margin increased to 29.4%, GAAP net income increased 25.8%, and adjusted operating income increased 14.5%.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net sales, three months ended September 30, 2026GAAP | $172.4M | – | 11.6% |
| Net sales, nine months ended September 30, 2026GAAP | $500.6M | – | 10.3% |
| Cost of sales, three months ended September 30, 2026GAAP | 121.7M | – | – |
| Cost of sales, nine months ended September 30, 2026GAAP | 354.6M | – | – |
| Gross profit, three months ended September 30, 2026GAAP | 50.76M | – | – |
| Gross profit, nine months ended September 30, 2026GAAP | 146.0M | – | – |
| Gross margin, three months ended September 30, 2026GAAP | 29.4% | – | – |
| Gross margin, nine months ended September 30, 2026GAAP | 29.2% | – | – |
| Selling, general & administrative expenses, three months ended September 30, 2026GAAP | $23.2M | – | 21.4% |
| Selling, general & administrative expenses, nine months ended September 30, 2026GAAP | $66.9M | – | 18.5% |
| SG&A as a percentage of sales, three months ended September 30, 2026GAAP | 13.4% | – | – |
| SG&A as a percentage of sales, nine months ended September 30, 2026GAAP | 13.4% | – | – |
| Adjusted SG&A, three months ended September 30, 2026non-GAAP | $20.65M | – | – |
| Adjusted SG&A, nine months ended September 30, 2026non-GAAP | $59.47M | – | – |
| Adjusted SG&A as a percentage of sales, three months ended September 30, 2026non-GAAP | 12.0% | – | – |
| Adjusted SG&A as a percentage of sales, nine months ended September 30, 2026non-GAAP | 11.9% | – | – |
| Acquisition costs, three months ended September 30, 2026GAAP | 12K | – | – |
| Acquisition costs, nine months ended September 30, 2026GAAP | 84K | – | – |
| Change in fair value of contingent consideration, three months ended September 30, 2026GAAP | — | – | – |
| Change in fair value of contingent consideration, nine months ended September 30, 2026GAAP | — | – | – |
| Gain on disposal of property, plant & equipment, three months ended September 30, 2026GAAP | −9K | – | – |
| Gain on disposal of property, plant & equipment, nine months ended September 30, 2026GAAP | −41K | – | – |
| Operating income, three months ended September 30, 2026GAAP | $27.6M | – | 18.1% |
| Operating income, nine months ended September 30, 2026GAAP | $79.1M | – | 11.6% |
| Adjusted operating income, three months ended September 30, 2026non-GAAP | $30.1M | – | 14.5% |
| Adjusted operating income, nine months ended September 30, 2026non-GAAP | $86.6M | – | 9.0% |
| Interest expense, net, three months ended September 30, 2026GAAP | 1.49M | – | – |
| Interest expense, net, nine months ended September 30, 2026GAAP | 4.94M | – | – |
| Other income, three months ended September 30, 2026GAAP | −6K | – | – |
| Other income, nine months ended September 30, 2026GAAP | −24K | – | – |
| Income before income tax expense, three months ended September 30, 2026GAAP | 26.12M | – | – |
| Income before income tax expense, nine months ended September 30, 2026GAAP | 74.16M | – | – |
| Income tax expense, three months ended September 30, 2026GAAP | 5.50M | – | – |
| Income tax expense, nine months ended September 30, 2026GAAP | 15.19M | – | – |
| Net income, three months ended September 30, 2026GAAP | $20.6M | – | 25.8% |
| Net income, nine months ended September 30, 2026GAAP | $59M | – | 16.2% |
| Adjusted net income, three months ended September 30, 2026non-GAAP | $22.5M | – | 21.1% |
| Adjusted net income, nine months ended September 30, 2026non-GAAP | $64.5M | – | 13.0% |
| Net income per diluted share, three months ended September 30, 2026GAAP | $2.64 | – | – |
| Net income per diluted share, nine months ended September 30, 2026GAAP | $7.56 | – | – |
| Adjusted net income per diluted share outstanding, three months ended September 30, 2026non-GAAP | $2.88 | – | – |
| Adjusted net income per diluted share outstanding, nine months ended September 30, 2026non-GAAP | $8.28 | – | – |
| Weighted average diluted common shares outstanding, three months ended September 30, 2026GAAP | 7,806 | – | – |
| Weighted average diluted common shares outstanding, nine months ended September 30, 2026GAAP | 7,795 | – | – |
| Organic sales, three months ended September 30, 2026non-GAAP | $171.7M | – | 11.1% |
| Organic sales, nine months ended September 30, 2026non-GAAP | $490.0M | – | 7.9% |
| Net sales from acquired operations, three months ended September 30, 2026non-GAAP | −725K | – | – |
| Net sales from acquired operations, nine months ended September 30, 2026non-GAAP | −10.64M | – | – |
| EBITDA, three months ended September 30, 2026non-GAAP | $32.64M | – | – |
| EBITDA, nine months ended September 30, 2026non-GAAP | $93.98M | – | – |
| Adjusted EBITDA, three months ended September 30, 2026non-GAAP | $35.4M | – | 15.3% |
| Adjusted EBITDA, nine months ended September 30, 2026non-GAAP | $102.8M | – | 10.7% |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
What drove it
- Third-quarter organic sales growth was 11.1%.
- MedTech sales grew 12.5% in the third quarter, reflecting broad-based demand across the portfolio.
- Gross margin increased to 29.4% in the third quarter from 27.7% in the same quarter of 2025.
- Management cited scaling new programs in the Dominican Republic, margin improvements in legacy UFP operations, and investments that broadened capabilities.
- Management stated that its 2025 investment in TPI exceeded expectations and provides an initial position in injection molding.
- Management cited significant year-over-year progress at AJR in both the U.S. and the Dominican Republic.
Concerns
- SG&A increased 21.4% to $23.2 million in the third quarter, and SG&A as a percentage of sales increased to 13.4% from 12.3%.
- Adjusted SG&A as a percentage of sales increased to 12.0% in the third quarter from 10.7%.
- Management stated that scheduled program transfers to the Dominican Republic and margin improvement remain behind plan.
- The filing identifies customer concentration, new product and program launches, program-transfer execution, supply-chain and labor-force disruption, indebtedness and financing-covenant compliance as risks.
What to watch
- Execution of scheduled program transfers to the Dominican Republic and the pace of margin improvement.
- Performance of the DAS Medical capacity investment intended to support double-digit growth.
- Progress on acquisition opportunities, integration of recent investments, and the planned expansion of the credit facility.
- Customer demand and the performance of the Company’s two largest customers under supply agreements.
Balance sheet and cash flow
- Cash and cash equivalents were $20,625 (in thousands) as of September 30, 2026, compared with $20,301 (in thousands) as of December 31, 2025.
- Receivables, net were $97,154 (in thousands) as of September 30, 2026, compared with $82,914 (in thousands) as of December 31, 2025.
- Inventories were $98,148 (in thousands) as of September 30, 2026, compared with $86,856 (in thousands) as of December 31, 2025.
- Current portion of long-term debt was $12,500 (in thousands) as of September 30, 2026 and December 31, 2025.
- Long-term debt, excluding current installments, was $83,500 (in thousands) as of September 30, 2026, compared with $122,955 (in thousands) as of December 31, 2025.
- Total assets were $682,635 (in thousands) as of September 30, 2026, compared with $655,077 (in thousands) as of December 31, 2025.
- Total liabilities were $196,920 (in thousands) as of September 30, 2026, compared with $231,200 (in thousands) as of December 31, 2025.
- Total equity was $485,715 (in thousands) as of September 30, 2026, compared with $423,877 (in thousands) as of December 31, 2025.
Analysis
UFP Technologies reported broad third-quarter growth. Net sales increased 11.6% to $172.4 million, including 11.1% organic sales growth. Management attributed MedTech sales growth of 12.5% to broad-based demand across its portfolio. Through September, sales increased 10.3% to $500.6 million and organic growth was 7.9%.
Profitability improved despite higher overhead. Third-quarter gross margin increased to 29.4% from 27.7%, while GAAP operating income increased 18.1% to $27.6 million and adjusted operating income increased 14.5% to $30.1 million. GAAP net income increased 25.8% to $20.6 million, and GAAP diluted EPS was $2.64 compared with $2.11 in the same quarter of 2025. Adjusted diluted EPS was $2.88 compared with $2.39.
The principal cost offset was SG&A. Third-quarter SG&A increased 21.4% to $23.2 million, and the ratio to sales increased to 13.4% from 12.3%. Adjusted SG&A as a percentage of sales rose to 12.0% from 10.7%. Management cited scaling programs in the Dominican Republic, margin improvements in legacy operations, the TPI investment, and progress at AJR as operational developments, while also stating that Dominican Republic program transfers and margin improvement remain behind plan.
The balance sheet showed cash and cash equivalents of $20,625 (in thousands) and long-term debt, excluding current installments, of $83,500 (in thousands) at September 30, 2026. Management stated that it is working to expand its credit facility to support investment in larger businesses and noted progress on several acquisition opportunities. The release provided no quantitative financial outlook, so the next areas for attention are Dominican Republic transfer execution, DAS Medical capacity investment, acquisition activity, and credit-facility expansion.
Management, verbatim
Our third quarter and year-to-date results reflect continued solid execution across the UFP platform and progress toward our long-term growth strategy.
Mitch Rock, President and Chief Executive Officer
In the third quarter, sales grew 11.6%, including 11.1% organic growth, gross margins increased to 29.4%, and adjusted operating income grew 14.5%. MedTech sales grew 12.5%, reflecting broad-based demand across our portfolio.
Mitch Rock, President and Chief Executive Officer
However, scheduled program transfers to the Dominican Republic and margin improvement remain behind plan.
Mitch Rock, President and Chief Executive Officer
Not in the filing
stated, not guessed- Quantitative forward guidance for revenue, gross margin, operating expenses, tax rate, earnings, EBITDA, or other financial metrics was not provided.
- Prior-release outlook was not provided, so comparison of actual results with prior guidance is unavailable.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Share repurchases and dividends were not reported.
- Segment revenue was not reported.
- Sequential, prior-quarter comparisons were not reported.
- GAAP and adjusted EPS year-over-year percentage changes were not reported.
- A tax rate was not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
UFP Technologies is a Nasdaq‑listed contract development and manufacturing firm serving medical device and sterile packaging markets.
Ticker impact
UFP Technologies reported Q3 2026 results with net income up 25.8% and sales up 11.6% versus the prior year, marking the first public disclosure of these numbers.
likely upward as investors price in better‑than‑expected earnings and margin expansion
The 8‑K filing is the first release of the quarter's numbers, showing significant earnings and revenue growth that exceed typical expectations for a mid‑cap contract manufacturer.
Market effects
Highlights strength in the MedTech contract manufacturing sector, potentially boosting peers.
U.S. small‑cap market may see modest buying pressure from earnings‑driven traders.
Limited to investors focused on U.S. contract manufacturers and MedTech supply chains.
Counterpoint
If the market had already priced in strong growth, the modest margin expansion may not be enough to drive a rally.
Key entities
- ExecutiveMitch Rock
President and CEO who commented on the results.
